Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer

Kinuko Nagayoshi, Takashi Ueki, Kosuke Tashiro, Yusuke Mizuuchi, Tatsuya Manabe, Hiromitsu Araki, Yoshinao Oda, Satoru Kuhara, Masao Tanaka

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95% confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95% CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.

元の言語英語
ページ(範囲)539-546
ページ数8
ジャーナルOncology reports
33
発行部数2
DOI
出版物ステータス出版済み - 12 1 2015

Fingerprint

Galanin
Colorectal Neoplasms
Neoplasms
Recurrence
Survival
Confidence Intervals
Adjuvant Chemotherapy
Small Interfering RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer. / Nagayoshi, Kinuko; Ueki, Takashi; Tashiro, Kosuke; Mizuuchi, Yusuke; Manabe, Tatsuya; Araki, Hiromitsu; Oda, Yoshinao; Kuhara, Satoru; Tanaka, Masao.

:: Oncology reports, 巻 33, 番号 2, 01.12.2015, p. 539-546.

研究成果: ジャーナルへの寄稿記事

@article{6a0425b912234d23ba0274b6f7a7662d,
title = "Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer",
abstract = "Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95{\%} confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95{\%} CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.",
author = "Kinuko Nagayoshi and Takashi Ueki and Kosuke Tashiro and Yusuke Mizuuchi and Tatsuya Manabe and Hiromitsu Araki and Yoshinao Oda and Satoru Kuhara and Masao Tanaka",
year = "2015",
month = "12",
day = "1",
doi = "10.3892/or.2014.3660",
language = "English",
volume = "33",
pages = "539--546",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer

AU - Nagayoshi, Kinuko

AU - Ueki, Takashi

AU - Tashiro, Kosuke

AU - Mizuuchi, Yusuke

AU - Manabe, Tatsuya

AU - Araki, Hiromitsu

AU - Oda, Yoshinao

AU - Kuhara, Satoru

AU - Tanaka, Masao

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95% confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95% CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.

AB - Reliable predictors of tumor recurrence for patients with stage II colorectal cancer (CRC) are needed to select patients who should receive adjuvant chemotherapy. Although galanin (GAL) is expressed in several malignant tumors and is associated with cell proliferation and tumor growth, the prognostic value of GAL expression in CRC is poorly understood. We compared GAL expression between 56 patients with stage II and III CRC who developed tumor recurrences and 56 patients who did not. The clinical and prognostic significance of GAL expression was examined using our data and independent public datasets. We also analyzed the influence of GAL expression on the proliferation and invasive activity of CRC cells. Higher expression of GAL was associated with tumor recurrence among the CRC patients (P<0.001). Stage II CRC patients who presented with high expression levels of GAL had significantly poorer prognosis than those with low expression levels of GAL [5-year overall survival: hazard ratio (HR), 7.31; 95% confidence interval (CI), 2.38-24.04; P<0.001; 5-year recurrence-free survival: HR, 3.99; 95% CI, 1.61-9.44; P=0.004], but there was no association between GAL expression and survival in stage III CRC patients. These findings were supported by analysis of two public datasets. Functionally, siRNA-mediated silencing of GAL resulted in a significant decrease in the proliferative and invasive activities of CRC cells. In conclusion, high expression of GAL is associated with poor prognosis of stage II CRC patients and GAL expression may be related to the aggressive behavior of CRC.

UR - http://www.scopus.com/inward/record.url?scp=84919444079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919444079&partnerID=8YFLogxK

U2 - 10.3892/or.2014.3660

DO - 10.3892/or.2014.3660

M3 - Article

C2 - 25504183

AN - SCOPUS:84919444079

VL - 33

SP - 539

EP - 546

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -